絞り込み

17696

広告

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.

著者 Reolid A , Muñoz-Aceituno E , Rodríguez-Jiménez P , González-Rojano E , Llamas-Velasco M , Fraga J , Daudén E
Int J Dermatol.2019 Oct 12 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (63view , 0users)

Full Text Sources

Bullous pemphigoid (BP) has been associated with dipeptidyl peptidase-4 inhibitors (DPP4i). Clinical features, outcomes, and risk of BP for new DPP4i (linagliptin, saxagliptin, and alopgliptin) are not well established. Comparison of risk of BP appearance for DPP4i and other oral antidiabetic drugs (OADs) such as sodium glucose cotransporter 2 inhibitors has not been studied to date.
PMID: 31605541 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード